4//SEC Filing
Steinhart Richard I 4
Accession 0001104659-25-069701
CIK 0001720893other
Filed
Jul 21, 8:00 PM ET
Accepted
Jul 22, 8:26 PM ET
Size
9.1 KB
Accession
0001104659-25-069701
Insider Transaction Report
Form 4
Steinhart Richard I
Chief Financial Officer
Transactions
- Award
Common Stock
2025-07-22+4,375→ 5,816 total - Exercise/Conversion
Restricted Stock Units
2025-07-22−625→ 0 total→ Common Stock (625 underlying) - Exercise/Conversion
Common Stock
2025-07-22+625→ 6,441 total
Footnotes (3)
- [F1]The Issuer previously granted the Reporting Person an award of restricted stock units that would vest based on the Issuer's satisfaction of certain performance objectives and subject to the Reporting Person's continued service with the Issuer through July 22, 2025 (the "PSUs"). On July 22, 2025, the Compensation Committee of the Issuer's Board of Directors determined that performance conditions with respect to 4,375 PSUs had been satisfied and 4,375 shares of common stock became issuable to the Reporting Person on July 22, 2025.
- [F2]Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
- [F3]On July 22, 2024, the Reporting Person was granted 625 RSUs, which vested as to 100% of the total number of RSUs on the first anniversary of the grant date.
Documents
Issuer
BioXcel Therapeutics, Inc.
CIK 0001720893
Entity typeother
Related Parties
1- filerCIK 0001293789
Filing Metadata
- Form type
- 4
- Filed
- Jul 21, 8:00 PM ET
- Accepted
- Jul 22, 8:26 PM ET
- Size
- 9.1 KB